<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02439697</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.2 18thApril, 2015</org_study_id>
    <nct_id>NCT02439697</nct_id>
  </id_info>
  <brief_title>A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients</brief_title>
  <official_title>A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single-arm open-labeled cohort study on dialysis patients of the
      conversion from Aranesp® to NESP® for the treatment of anemia. The primary outcome of the
      study is the haemoglobin level after conversion to NESP® after 6 months. Secondary outcomes
      include the variability in haemoglobin level, average weekly dose of erythropoietin, safety
      profile of NESP®, patients' subjective assessment of fatigue and injection pain after the
      conversion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently in Hong Kong, Aranesp®, manufactured by Amgen® is the only available Darbepoetin
      alpha licensed. NESP®, a Darbepoetin alpha agent manufactured by Kirin®, will be replacing
      Aranesp®.It is important to evaluate the therapeutic equivalence of the two agents, and its
      efficacy, tolerability and safety profile in the treatment of anemia in dialysis patients.
      Moreover, a new maximum preparation of NESP 120® microgram will be available to replace the
      Aranesp® 100 microgram prefilled syringe at the same cost. This larger Darbepoetin alpha
      preparation may allow extension of dosing intervals. This may subsequently allow cost saving
      and better convenience to medical staff and patients.

      The objectives of this project are:

        1. To investigate the effectiveness of NESP® in the achieving a stable anemia control in
           chronic dialysis patients with the same dose conversion from Aranesp®

        2. To investigate the effectiveness of increasing the dosing interval of NESP® (but
           maintaining the same total dose) in sustaining a stable anemia control in chronic
           dialysis patients

        3. To explore the possibility of cost saving in administering a larger dose NESP® but at an
           extended interval

           Patients will be divided into 3 groups.

           Group A. Same dose conversion group

           • Patients on stable low dose Aranesp® (on 20mcg preparations or on 40mcg every 2 weeks
           or less) will be converted to the same dose of NESP®

           Group B. Attempt extension of dosing interval with higher dose of NESP® preparations

           • Patients on stable dose of Aranesp® will be converted to higher dose preparation of
           NESP® (40 or 120 mcg preparations) with extended dosing intervals.

           Group C. Attempt dosage saving with 120 mcg preparation

           • Patients on Aranesp® 100mcg will be switched to the NESP® 120mcg preparation with
           slight increase in dosing interval
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haemoglobin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variability in haemoglobin level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average weekly dose of erythropoietin</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety profile of NESP</measure>
    <time_frame>6 months</time_frame>
    <description>Blood pressure, Questionnaire on the occurrence of side-effects such as seizure, pure red cell aplasia, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective assessment of fatigue</measure>
    <time_frame>6 months</time_frame>
    <description>Visual Analogue Fatigue Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective assessment of pain</measure>
    <time_frame>6 months</time_frame>
    <description>Numeric Pain Numeric Pain Rating Scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Anemia</condition>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <arm_group>
    <arm_group_label>Darbepoetin alfa (NESP®) same dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on stable low dose Aranesp® (darbepoetin alfa manufactured by Amgen®) (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP® (darbepoetin alfa manufactured by Kirin®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended dosing Darbepoetin alfa (NESP®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on stable dose of Aranesp® (darbepoetin alfa manufactured by Amgen®) will be converted to higher dose preparation of NESP® (darbepoetin alfa manufactured by Kirin®) 40 or 120 mcg preparations) with extended dosing intervals. The total dose of Darbepoetin alpha remains the same.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darbepoetin alfa (NESP®) 120mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on Aranesp® 100 mcg preparation (darbepoetin alfa manufactured by Amgen®) will be switched to the NESP® (darbepoetin alfa manufactured by Kirin®)120mcg preparation with slight increase in dosing interval according to the conversion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Conversion from Aranesp® to NESP®</description>
    <arm_group_label>Darbepoetin alfa (NESP®) same dose</arm_group_label>
    <arm_group_label>Extended dosing Darbepoetin alfa (NESP®)</arm_group_label>
    <arm_group_label>Darbepoetin alfa (NESP®) 120mcg</arm_group_label>
    <other_name>NESP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Chinese patients (age greater than or equal to 18)

          -  on long-term dialysis for at least 3 months

          -  on Aranesp® treatment for at least 3 months

          -  stable hemoglobin level within the range of 9 to12 g/dL, on the same stable dose of
             Aranesp® within the past 2 months.

          -  Minimum weekly kT/V of 1.7 for peritoneal dialysis patients and 1.2 per haemodialysis
             session for haemodialysis patients

          -  Able to give informed consent

        Exclusion Criteria:

        Presence of

          -  thalassaemia

          -  haematological diseases

          -  severe hyperparathyroidism (PTH &gt;90 pmol/L)

          -  iron, vitamin B12 or folate deficiency

          -  uncontrolled malignancy

          -  active blood loss or hemolysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie Ming Yee Mok, MBBS FHKAM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hosptial, the University of Hong KOng</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tak Mao Chan, MBBS FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Queen Mary Hospital, the University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maggie Ming Yee Mok, MBBS FHKAM</last_name>
    <phone>22553111</phone>
    <email>maggiemymok@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tak Mao Chan, MBBS FRCP</last_name>
    <phone>22554542</phone>
    <email>dtmchan@hku.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Medicine, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Ming Yee Mok, MBBS FHKAM</last_name>
      <phone>852-22553111</phone>
      <email>maggiemymok@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tak Mao Chan, MBBS FRCP</last_name>
      <phone>852-22554542</phone>
      <email>dtmchan@hku.hk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <reference>
    <citation>Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ; European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002 Dec;62(6):2167-75.</citation>
    <PMID>12427142</PMID>
  </reference>
  <reference>
    <citation>Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, Farouk M. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant. 2012 Jun;27(6):2303-11. doi: 10.1093/ndt/gfr677. Epub 2011 Dec 2.</citation>
    <PMID>22140136</PMID>
  </reference>
  <reference>
    <citation>Hiramatsu M, Kubota M, Iwasaki M, Akizawa T, Koshikawa S; KRN321 A09 Study Group. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients. Ther Apher Dial. 2008 Feb;12(1):19-27. doi: 10.1111/j.1744-9987.2007.00525.x.</citation>
    <PMID>18257808</PMID>
  </reference>
  <reference>
    <citation>Suzuki H, Inoue T, Watanabe Y, Kikuta T, Sato T, Tsuda M, Uchida K. Testing a single monthly dose of darbepoetin alpha to maintain hemoglobin levels in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 2011;27:60-4.</citation>
    <PMID>22073831</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2015</study_first_posted>
  <last_update_submitted>October 24, 2016</last_update_submitted>
  <last_update_submitted_qc>October 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Mok Ming Yee</investigator_full_name>
    <investigator_title>Resident Specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

